A Poly-N-AcetylglucosamineShiga Toxin Broad-Spectrum Conjugate Vaccine for Shiga Toxin-Producing Escherichia coli

Many pathogens produce the (cid:3) -(1 (cid:2) 6)-linked poly- N -acetylglucosamine (PNAG) surface polysaccharide that is being developed as a broadly protective antimicrobial vaccine. However, it is unknown whether systemically injected PNAG vaccines or antibodies would provide protective immunity against pathogens confined to the gastrointestinal tract such as Shiga toxin (Stx)-producing Escherichia coli (STEC), an important group of gastrointestinal (GI) pathogens for which effective immunotherapeutics are lacking. To ascertain whether systemic IgG antibody to PNAG impacts this infectious situation, a vaccine consisting of a synthetic nonamer of nonacetylated PNAG, 9GlcNH 2 , conjugated to the Shiga toxin 1b subunit (9GlcNH 2 -Stx1b) was produced. Rabbit antibodies raised to the conjugate vaccine were tested for bacterial killing and toxin neutralization in vitro and protection against infection in infant mice. Cell surface PNAG was detected on all 9 STEC isolates tested, representing 6 STEC serogroups, including E. coli O157:H7. Antibody to the 9GlcNH 2 -Stx1b conjugate neutralized Stx1 potently and Stx2 modestly. For O157:H7 and O104:H4 STEC strains, antibodies elicited by the 9GlcNH 2 -Stx1b conjugate possessed opsonic killing and bactericidal activity. Following intraperitoneal injection, antibodies to both PNAG and Stx were needed for infant mouse protection against O157 STEC. These antibodies also mediated protection against the Stx2-producing O104:H4 strain that was the cause of a recent outbreak in Germany, although sufficient doses of antibody to PNAG alone were protective against this strain in infant mice. Our observations suggest that vaccination against both PNAG and Stx, using a construct such as the 9GlcNH 2 -Stx1b conjugate vaccine, would be protective against a broad range of STEC serogroups. in infant mice. All nine (100%) clinical strains of STEC from different serogroups expressed PNAG. Vaccine-induced antibody mediated in vitro killing of STEC and neutralization of both Stx1 and Stx2. Passive administration of antibody to the conjugate showed protection requiring immunity to both PNAG and Stx for O157 strains, although for an O104 strain, antibody to PNAG alone was protective. Immunity to PNAG may contribute to protection against STEC infections.

[1]  E. Schadt,et al.  Autotransporters but not pAA are critical for rabbit colonization by Shiga toxin-producing Escherichia coli O104:H4 , 2014, Nature Communications.

[2]  P. Tarr,et al.  Treatment of Shiga toxin-producing Escherichia coli infections. , 2013, Infectious disease clinics of North America.

[3]  M. Palermo,et al.  Immunization with a Chimera Consisting of the B Subunit of Shiga Toxin Type 2 and Brucella Lumazine Synthase Confers Total Protection against Shiga Toxins in Mice , 2013, The Journal of Immunology.

[4]  W. Liles,et al.  Enterohemorrhagic Escherichia coli Infections and the Hemolytic-Uremic Syndrome. , 2013, The Medical clinics of North America.

[5]  W. Garrett,et al.  Antibody to a conserved antigenic target is protective against diverse prokaryotic and eukaryotic pathogens , 2013, Proceedings of the National Academy of Sciences.

[6]  D. Sarracino,et al.  Comparison of Immune Responses to the O-Specific Polysaccharide and Lipopolysaccharide of Vibrio cholerae O1 in Bangladeshi Adult Patients with Cholera , 2012, Clinical and Vaccine Immunology.

[7]  Klaus Stark,et al.  Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. , 2011, The New England journal of medicine.

[8]  H. Liu,et al.  Novel fusion protein protects against adherence and toxicity of enterohemorrhagic Escherichia coli O157:H7 in mice. , 2011, Vaccine.

[9]  James H. Bullard,et al.  Origins of the E. coli strain causing an outbreak of hemolytic-uremic syndrome in Germany. , 2011, The New England journal of medicine.

[10]  A. O’Brien,et al.  Mouse Models of Escherichia coli O157:H7 Infection and Shiga Toxin Injection , 2011, Journal of biomedicine & biotechnology.

[11]  M. Widdowson,et al.  Foodborne Illness Acquired in the United States—Major Pathogens , 2011, Emerging infectious diseases.

[12]  D. Friedmann,et al.  Molecular Basis of Differential B-Pentamer Stability of Shiga Toxins 1 and 2 , 2010, PloS one.

[13]  G. Pier,et al.  Synthetic β-(1→6)-Linked N-Acetylated and Nonacetylated Oligoglucosamines Used To Produce Conjugate Vaccines for Bacterial Pathogens , 2009, Infection and Immunity.

[14]  L. Hammarström,et al.  Individuals with selective IgA deficiency resolve rotavirus disease and develop higher antibody titers (IgG, IgG1) than IgA competent individuals , 2008, Journal of medical virology.

[15]  M. Noda,et al.  Receptor affinity, stability and binding mode of Shiga toxins are determinants of toxicity. , 2007, Microbial pathogenesis.

[16]  D. Goldmann,et al.  Protection against Escherichia coli infection by antibody to the Staphylococcus aureus poly-N-acetylglucosamine surface polysaccharide , 2007, Proceedings of the National Academy of Sciences.

[17]  D. Goldmann,et al.  Molecular Basis for Preferential Protective Efficacy of Antibodies Directed to the Poorly Acetylated Form of Staphylococcal Poly-N-Acetyl-β-(1-6)-Glucosamine , 2007, Infection and Immunity.

[18]  G. Pier,et al.  Synthesis of beta-(1-->6)-linked glucosamine oligosaccharides corresponding to fragments of the bacterial surface polysaccharide poly-N-acetylglucosamine. , 2007, Carbohydrate research.

[19]  D. Goldmann,et al.  Characterization of the Opsonic and Protective Activity against Staphylococcus aureus of Fully Human Monoclonal Antibodies Specific for the Bacterial Surface Polysaccharide Poly-N-Acetylglucosamine , 2006, Infection and Immunity.

[20]  Y. Shiloach,et al.  Safety and immunogenicity of Escherichia coli O157 O-specific polysaccharide conjugate vaccine in 2-5-year-old children. , 2006, The Journal of infectious diseases.

[21]  D. Goldmann,et al.  Poly-N-Acetylglucosamine Production in Staphylococcus aureus Is Essential for Virulence in Murine Models of Systemic Infection , 2005, Infection and Immunity.

[22]  D. Goldmann,et al.  Comparative Opsonic and Protective Activities of Staphylococcus aureus Conjugate Vaccines Containing Native or Deacetylated Staphylococcal Poly-N-Acetyl-β-(1-6)-Glucosamine , 2005, Infection and Immunity.

[23]  L M Thomas,et al.  Structural analysis of dispersin B, a biofilm-releasing glycoside hydrolase from the periodontopathogen Actinobacillus actinomycetemcomitans. , 2005, Journal of molecular biology.

[24]  D. Roopenian,et al.  Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. , 2004, Immunity.

[25]  C. Thorpe.  Shiga toxin-producing Escherichia coli infection. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  M. Waldor,et al.  Role for a Phage Promoter in Shiga Toxin 2 Expression from a Pathogenic Escherichia coliStrain , 2001, Journal of bacteriology.

[27]  Craig S. Wong,et al.  The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. , 2000, The New England journal of medicine.

[28]  M. Waldor,et al.  Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. , 2000, The Journal of infectious diseases.

[29]  D. Goldmann,et al.  Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. , 1999, Science.

[30]  D. Greenberg,et al.  Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. , 1996, The Journal of infectious diseases.

[31]  J. Samuel,et al.  Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice , 1993, Infection and immunity.

[32]  L. M. Sung,et al.  Acute renal tubular necrosis and death of mice orally infected with Escherichia coli strains that produce Shiga-like toxin type II , 1990, Infection and immunity.

[33]  D. Acheson,et al.  Purification of Shiga toxin and Shiga-like toxins I and II by receptor analog affinity chromatography with immobilized P1 glycoprotein and production of cross-reactive monoclonal antibodies , 1989, Infection and immunity.

[34]  C. Cunningham-Rundles.  Selective IgA deficiency. , 1988, Journal of pediatric gastroenterology and nutrition.

[35]  M. Petric,et al.  SPORADIC CASES OF HAEMOLYTIC-URAEMIC SYNDROME ASSOCIATED WITH FAECAL CYTOTOXIN AND CYTOTOXIN-PRODUCING ESCHERICHIA COLI IN STOOLS , 1983, The Lancet.

[36]  S. Collins,et al.  Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture , 1977, Nature.